RT Journal Article
T1 Association of Sentinel Node Biopsy and Pathological Report Completeness with Survival Benefit for Cutaneous Melanoma and Factors Influencing Their Different Uses in European Populations.
A1 Sant, Milena
A1 Magri, Maria Chiara
A1 Maurichi, Andrea
A1 Lillini, Roberto
A1 Bento, Maria Jose
A1 Ardanaz, Eva
A1 Guevara, Marcela
A1 Innos, Kaire
A1 Marcos-Gragera, Rafael
A1 Rubio-Casadevall, Jordi
A1 Sanchez-Perez, Maria-Jose
A1 Tumino, Rosario
A1 Rugge, Massimo
A1 Minicozzi, Pamela
K1 cutaneous melanoma
K1 excess of relative risk of death
K1 pathology report
K1 population-based cancer registries
K1 relative survival
K1 sentinel lymph node biopsy
AB Objectives: Standard care for cutaneous melanoma includes an accurate pathology report (PR) and sentinel lymph node biopsy (SLNB) for staging clinically node-negative >1 mm melanomas. We aimed to investigate the frequency of these indicators across European countries, also assessing consequences for survival. Methods: We analyzed 4245 melanoma cases diagnosed in six European countries in 2009−2013. Multivariable logistic regression was used to estimate the Odds Ratio (OR) of receiving complete PR with eight items or SLNB and model-based survival to estimate the five-year relative excess risks of death (RER). Results: Overall, 12% patients received a complete PR (range 2.3%, Estonia—20.1%, Italy); SLNB was performed for 68.8% of those with cN0cM0 stage (range 54.4%, Spain—81.7%, Portugal). The adjusted OR of receiving a complete PR was lower than the mean in Estonia (OR 0.11 (0.06−0.18)) and higher in Italy (OR 6.39 (4.90−8.34)) and Portugal (OR 1.39 (1.02−1.89)); it was higher for patients operated on in specialized than general hospitals (OR 1.42 (1.08−1.42)). In the multivariate models adjusted for age, sex, country and clinical-pathological characteristics, the RER resulted in being higher than the reference for patients not receiving a complete PR with eight items (RER 1.72 (1.08−2.72)), or for those not undergoing SLNB (RER 1.76 (1.26−2.47)) Patients with non-metastatic node-negative thickness >1 mm melanoma who did not undergo SLNB had a higher risk of death (RER (RER 1.69 (1.02−2.80)) than those who did. Conclusions: Accurate pathology profiling and SLNB carried survival benefit. Narrowing down between-countries differences in adhesion to guidelines might achieve better outcomes.
PB MDPI AG
SN 2072-6694
YR 2022
FD 2022-08-31
LK http://hdl.handle.net/10668/20916
UL http://hdl.handle.net/10668/20916
LA en
NO Sant M, Magri MC, Maurichi A, Lillini R, Bento MJ, Ardanaz E, et al. The Melanoma Hr Study Working Group. Association of Sentinel Node Biopsy and Pathological Report Completeness with Survival Benefit for Cutaneous Melanoma and Factors Influencing Their Different Uses in European Populations. Cancers (Basel). 2022 Sep 8;14(18):4379.
DS RISalud
RD Apr 6, 2025